Sign In
Buy BEAM
$29.55
+0.590 (+2.04%)
At Close: Jun 03, 2026
Cathie Wood Loves This Beaten-Down Stock. But Is It in Trouble?
05:50am, Wednesday, 25'th Oct 2023
Cathie Wood has made big bets on base-editing stocks, including recent purchases of Beam Therapeutics. However, Beam announced a reprioritization of its pipeline last week, raising concerns for invest
Beam: Opportunity Based On SCD Data Readout In 2024
06:39am, Sunday, 22'nd Oct 2023
Beam Therapeutics is progressing well with its phase 1/2 BEACON study using BEAM-101 for severe sickle cell disease treatment; Data expected in 2024. The company has chosen to cut out several programs
Beam Therapeutics Stock: Bear vs. Bull
08:45am, Saturday, 21'st Oct 2023
Pre-revenue biotechs like Beam Therapeutics bring plenty of risk. The good news is that it has plenty of money and some help from Pfizer, too.
BEAM to Reprioritize Portfolio, Slash Jobs, Shares Tank
12:47pm, Friday, 20'th Oct 2023
BEAM announces a restructuring and portfolio reprioritization plan to focus on genome-editing candidate, BEAM-101. The company is set to reduce its workforce by almost 20%.
Beam Therapeutics to cut 20% of workforce as part of restructuring plan
09:06am, Thursday, 19'th Oct 2023
Beam Therapeutics said on Thursday it plans to reduce its headcount by about 100 employees, or 20% of its current workforce, as part of a restructuring plan.
Beam Therapeutics to reduce staff by 20% as it seeks to extend cash runway into 2026
08:56am, Thursday, 19'th Oct 2023
Beam Therapeutics Inc. BEAM, -6.60% said Thursday it will reduce headcount by 100 employees, or about 20% of its workforce, to help it extend its cash runway into 2026. The Cambridge, Mass.
1 Risky Biotech Stock to Consider Buying, and 1 to Avoid
09:30am, Wednesday, 18'th Oct 2023
Don't buy biotech stocks unless your portfolio is properly diversified already. Beam Therapeutics might eventually have a competitive advantage in manufacturing.
BEAM Focuses on Developing Gene Drug for Growth
11:16am, Tuesday, 10'th Oct 2023
While BEAM's pipeline candidates are in early-stage clinical studies, their development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.
2 Cathie Wood Stocks I'm Bullish On
08:45am, Thursday, 05'th Oct 2023
Investor Cathie Wood has an eye for powerful trends in high-tech areas of the market. She has been hitting the buy button lately on Beam Therapeutics and Recursion Pharmaceuticals.
3 Stocks Cathie Wood Is Buying That Should Be on Your List, Too
05:50am, Friday, 22'nd Sep 2023
Beam Therapeutics is pioneering a promising type of gene editing. Recursion Pharmaceuticals is harnessing AI to improve drug discovery.
2 Cutting-Edge Gene-Editing Stocks That You Don't Want to Miss
09:37am, Tuesday, 19'th Sep 2023
Gene-editing therapies are among the most powerful medicines to ever exist. Wave Life Sciences is taking aim at two rare diseases, but it's short on cash.
This Cathie Wood Stock Is Down 40% in 2023. Here's Why She's Still Buying It.
08:20am, Friday, 08'th Sep 2023
Cathie Wood is buying shares of Beam Therapeutics even though they are down. Stocks can fall for all sorts of reasons that aren't relevant in the long term.
Cathie Wood's Buying These 3 Stocks Hand Over Fist
07:23am, Friday, 08'th Sep 2023
Cathie Wood recently bought shares of Beam Therapeutics, a clinical-stage drugmaker testing out a new way to edit troublesome genes. Ark Invest also acquired shares of Pacific Biosciences of Californi
Beam Therapeutics to Participate in Upcoming September Investor Conferences
06:30am, Thursday, 31'st Aug 2023
CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man
3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street
07:50am, Saturday, 26'th Aug 2023
Cathie Wood is an icon in the world of disruptive tech. Her firm ARK Invest holds positions in Beam Therapeutics, COMPASS Pathways, and 908 Devices.
